The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival (EFS) and relapse at 5 years were 44%, 32%, 49% following TBI/CY/E and 42%, 34% and 42% following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32% after Bu/Mel/T therapy. Transplant-related mortality was 16% for TBI/CY/E and 21% for Bu/Mel/T. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome ( but almost all of these patients relapse and die, despite salvage treatment. Thirty to 60% of patients with aggressive NHL can be cured with intensive chemotherapy. However, the 2-year survival for patients who fail or relapse after induction chemotherapy is only 5 to 10%. High-dose chemotherapy (HDC) supported with autologous stem cell infusion (ASCI) has proven efficacy in patients with first or subsequent chemotherapy-sensitive relapse, as well as in those patients who fail induction chemotherapy.
but almost all of these patients relapse and die, despite salvage treatment. Thirty to 60% of patients with aggressive NHL can be cured with intensive chemotherapy. However, the 2-year survival for patients who fail or relapse after induction chemotherapy is only 5 to 10%. 1 High-dose chemotherapy (HDC) supported with autologous stem cell infusion (ASCI) has proven efficacy in patients with first or subsequent chemotherapy-sensitive relapse, as well as in those patients who fail induction chemotherapy. 2 Radiation-based and chemotherapy-only preparative regimens have been evaluated in patients with NHL. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, the superiority of a specific HDC conditioning regimen for NHL has not been proven and few comparisons between regimens have been reported. [12] [13] [14] [15] The Fred Hutchinson Cancer Research Center (FHCRC) has evaluated both radiation-based and chemotherapy-only conditioning regimens for the treatment of lymphomas. Phase II studies of both approaches have previously been published. 3, 8, [16] [17] [18] High-dose fractionated total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) followed by ASCI was evaluated in patients with NHL (n = 43) and Hodgkin's disease (n = 10) who had failed to achieve a complete response after conventional chemotherapy or who had chemosensitive relapse. The 2-year Kaplan-Meier (KM) probabilities of survival, event-free survival (EFS) and relapse were 54%, 45% and 43%, respectively. The treatment-related mortality (TRM) was 17%. 16 Twenty-three patients with NHL and 17 with Hodgkin's disease were treated with the high-dose regimen of Busulfan (Bu), Melphalan (Mel) and Thiotepa (T) (Bu/Mel/T). The 2-year KM estimates of survival, EFS and relapse were 60%, 46% and 31%, respectively with a transplant-related mortality of 17%. 18 Randomized trials comparing the efficacy and toxicity between TBI-based and non-TBI regimens for patients with NHL have not been reported. With a larger number of patients and longer follow-up available to us, we compared outcomes and toxicities of patients with NHL treated with TBI/CY/E or Bu/Mel/T regimen.
Patients and methods
Between September 1990 and July 1998, 351 patients with all histologic grades of NHL were enrolled in phase II trials evaluating two preparative regimens: TBI/CY/E (n = 221) and Bu/Mel/T (n = 130). All patients were treated within protocols approved by the institutional review board of the FHCRC or Puget Sound Oncology Consortium (PSOC) and a protocol-specific consent was signed. PSOC participants have been reported elsewhere. 19 Patients were assigned to TBI/CY/E regimen starting in 1990. Eligibility for this study was restricted to patients who had not received doselimiting radiation (defined below). Patients ineligible for a TBI-based regimen were offered a regimen of carmustine, etoposide and cyclophosphamide (CBV). Patients treated with CBV have been previously reported and are not included in this analysis. 8 Beginning in 1993 patients who could not receive a TBI-based regimen were offered the Bu/Mel/T regimen. As experience was gained with this regimen, in 1995, Bu/Mel/T was also offered to patients who had not received dose-limiting radiation therapy. After 1995, physician preference determined which conditioning regimen was administered to patients who had not received dose-limiting irradiation.
NHL was classified according to the Working Formulation (WF). 20 Patients aged 12-65 years (up to 70 years for Bu/Mel/T) were eligible for both preparative regimens if they had failed primary treatment or were in first complete remission with high risk of relapse. Before the International Prognostic Index (IPI) 21 was introduced, high risk of relapse criteria included patients in first remission with Burkitt lymphoma or patients not achieving complete remission (CR) status after three cycles of conventional chemotherapy. Later, high-risk for relapse included mantle cell histology or aggressive lymphoma with three IPI risk factors at the time of diagnosis. These risk factors were: for patients у60 years; lactic dehydrogenase (LDH) levels greater than one times normal; stage III/IV disease; Eastern Cooperative Oncology Group (ECOG) performance status 2-4 or equivalent; Karnofsky score р60 (the patient was not ambulatory); Ͼ1 site of involvement; or for patients Ͻ60 years: elevated LDH, stage III/IV disease, and ECOG performance status of 2-4. Inclusion criteria were a bilirubin Ͻ2 mg/dl, creatinine Ͻ2.0, pulmonary function as measured by a diffusion lung capacity for carbon monoxide (DLCO) Ͼ60%, and a cardiac function measured by ejection fraction (EF) Ͼ40% and a Karnofsky score of Ͼ70. Exclusion criteria for TBI/CY/E regimen were patients with a history of greater than 20 Gy of prior radiation therapy to the liver or mediastinum or greater than 30 Gy to the central nervous system (CNS). Patients with prior doselimiting radiation were included in the Bu/Mel/T protocol. Pre-treatment evaluation has been described elsewhere. [16] [17] [18] Based on the clinical history prior to peripheral blood stem cell (PBSC) mobilization and HDC/ASCI, patients in first or second remission and/or with untreated or chemotherapy-sensitive first relapse were classified as having less advanced disease while all other patients were considered to have more advanced disease. [16] [17] [18] In this study, indolent lymphoma included only those patients with follicular, predominantly small cleaved cell (FSC); follicular, mixed small cleaved and large cell (FM) and follicular, predominantly large cell (FL). Aggressive lymphoma included patients with diffuse, small cleaved cell (DSC), diffuse mixed, small and large cell (DM), diffuse, large cell cleaved or noncleaved cell (DL) and those patients classified by WF as high-grade lymphomas. 20 
Patient characteristics
TBI/CY/E and Bu/Mel/T regimens: Three hundred and fifty-one patients with NHL and a median age of 47 years were treated. Table 1 shows patient characteristics. Two hundred and twenty-one (63%) patients received TBI/CY/E, and 130 (37%) received Bu/Mel/T. More patients receiving TBI/CY/E had bone marrow involvement before transplantation compared to patients receiving Bu/Mel/T (15% vs 5% P = 0.004). There were more patients older than 60 years and with aggressive histology who received Bu/Mel/T (P Ͻ 0.005). Forty-five percent of the patients conditioned with Bu/Mel/T had prior doselimiting radiation therapy and were not eligible to receive TBI/CY/E.
HDC regimens TBI/CY/E:
Patients received 12 Gy TBI, delivered in 1.5 Gy fractions twice a day for 4 days, with fractions separated by at least 6 h from a dual cobalt-60 source, at a dose rate of 6 to 7 cGy/min (n = 85) or via linear accelerator at 8 cGy/min (n = 136). Intravenous (i.v.) infusion of E (60 mg/kg or 30 mg/kg for patients age Ͼ55 years old) over 4 h was administered on day −4, followed by a day of rest. CY (100 mg/kg or 60 mg/kg for patients age Ͼ55 years) was infused over 1-2 h on day −2, followed by a day of rest. Stem cells were infused on day 0.
16,17
Bu/Mel/T: Twenty-four hours before the first dose of busulfan, all patients received phenytoin continuing until 24 h after the final dose of busulfan. Patients received busulfan 1 mg/kg/dose p.o. every 6 h on days −8, −7, and −6 for a total dose of 12 mg/kg. Melphalan (50 mg/m 2 i.v. per day) was given on days −5 and −4 for a total dose of 100 mg/m 2 . Thiotepa (250 mg/m 2 i.v. per day) was administered on days −3 and −2 for a total dose of 500 mg/m 2 . Stem cells were infused 48 h after the last dose of thiotepa. 18 
Supportive care
Prophylactic systemic antibiotics were administered when the absolute neutrophil count (ANC) was Ͻ0.5 × 10 9 /l and were discontinued after neutrophil engraftment with 0.5 × 10 9 /l. Patients who were serologically positive for cytomegalovirus and/or herpes simplex virus were treated with prophylactic acyclovir. Platelet transfusions were administered when the platelet level was Ͻ20 × 10 9 /l.
Bone marrow and PBSC collection, cryopreservation, and infusion
The techniques for marrow aspiration and PBSC harvest following the administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone or with chemotherapy, cryopreservation, thawing and infusion have been described. [22] [23] [24] Table 1 shows the number of patients receiving bone marrow or PBSC, as well as the number of patients who had marrow incubated in vitro with anti-B cell or anti-T cell monoclonal antibodies and complement. 25, 26 PBSC were mobilized mainly with chemotherapy and G-CSF and were not purged. 23, 27 The combination of CY/E was the most common regimen used for PBSC mobilization (n = 131). Other chemotherapy regimens were dexamethasone, cytarabine and cisplatin (DHAP) (n = 20), CY alone (n = 17), CY taxol (n = 11), cyclophosphamide, etoposide and cisplatin (CEP) (n = 12), etoposide, high-dose ara-C, methylprednisolone and cisplatin (ESHAP), mesna, ifosfamide, mitoxantrone, and etoposide (MINE) (n = 7).
Bone Marrow Transplantation

Post-transplant treatment
In order to prevent CNS relapse, all patients with highgrade lymphomas were treated with intrathecal methotrexate. A total of eight doses at 12 mg/m 2 were administered, two doses were given prior to transplantation and six doses post-transplant. Male patients with high-grade NHL received 4 Gy of testicular irradiation prior to transplant. Hematopoietic growth factors such as (rhG-CSF), recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), recombinant human interleukin 3 (rhIL-3) and granulocyte-macrophage colony-stimulating factor-interleukin-3 fusion protein, (PIXY321) were administered on day 1 after transplant to 154 (44%) patients (TBI, n = 73; Bu/Mel/T, n = 81). A subgroup of 52 patients who engrafted, without major organ toxicity or infection, with CR, PR or stable disease and not receiving corticosteroids were treated with interleukin-2 (IL-2) with or without lymphokine-activated killer cells within 24 to 58 days posttransplant. 28 A higher percentage of patients treated with TBI/CY/E (n = 44) received immunotherapy compared to Bu/Mel/T (n = 8) (20% vs 6%, P Ͻ 0.001). Nine patients were treated with interferon alpha 2a, six of these patients were conditioned with TBI/CY/E and one patient received rituximab after Bu/Mel/T treatment.
Twenty-two patients (6%) received local radiation therapy post-transplant to sites of persistent disease (Table 1) . Restaging to assess all sites of prior disease was performed at 60 days post-transplant, 1 year and thereafter according to clinical indications.
Regimen-related toxicity (RRT)
Toxicity was assessed according to the Bearman score. 29 Idiopathic pneumonia syndrome (IPS) was defined as pulmonary infiltrates without infectious etiology. 30 The diagnosis of veno-occlusive disease (VOD) was made on the basis of hepatomegaly and/or liver tenderness, weight gain Ͼ2% of baseline and an elevated serum bilirubin Ͼ2 mg/dl and/or histologically with damage to the endothelial cells at the termini of hepatic venules, dilatation of the sinusoids and necrosis of hepatocytes. 31 
Statistical analysis
Outcomes examined included survival and EFS and were calculated from day 0 of transplantation. Comparison of proportions was made with the Fisher's test. Probabilities of survival were estimated from day 0 to day of last contact and from day 0 to the date of death or relapse censored by the date of last contact according to the method of cumulative incidence estimates. 32 The log-rank test was used to compare survival curves. Univariate, multivariate and stepwise Cox regression analyses were performed to identify prognostic factors associated with survival, EFS, TRM and RRT. Age, sex, histology, status of disease before transplantation, bone marrow involvement, graft source, bone marrow purging, prior dose-limiting radiation therapy and post-transplant treatment with IL-2 were evaluated for the entire group and according to the HDC regimen.
Results
Engraftment
Twenty-nine (8%) of 351 patients died without neutrophil or platelet engraftment before day 30 and were excluded for engraftment analysis. Patients who received PBSC recovered neutrophil and platelet counts significantly sooner than recipients of BM, irrespective of the HDC regimen 14 vs 10 and 22 vs 11 days, respectively (P = 0.005). There were no differences in engraftment between patients receiving TBI/CY/E or Bu/Mel/T and the same sources of stem cells.
Toxicity
Regimen-related toxicity: The most common grade 3 toxicities after TBI/CY/E treatment were pulmonary (4%) and renal (3%) and after Bu/Mel/T were gastrointestinal (5%), hepatic (3%), renal (2%), oral (2%) and pulmonary (1%). Hemorrhagic cystitis was observed in 1% of patients receiving each of the regimens. Regimen-related mortality occurred in 18 (8%) of 221 patients who received TBI/CY/E. Thirteen (6%) and five (2%) patients developed IPS and cardiac toxicity, respectively, and died. Fourteen (11%) of 130 patients treated with Bu/Mel/T died secondary to RRT. Six (8%) of 71 patients without prior doselimiting radiation therapy died secondary to VOD (n = 4) and IPS (n = 2). The causes of death in eight (14%) of 59 patients who had dose-limiting radiation therapy were VOD (n = 4) and IPS (n = 4). There were no statistically significant differences when the rate of RRT in patients receiving TBI was compared to that in patients treated with Bu/Mel/T therapy (8% vs 11% P = 0.9).
Deaths from infection: Fifteen (7%) infection-related deaths occurred in patients receiving TBI/CY/E. Eight fatal infections were bacterial, four fungal, two viral and one Pneumocystis carinii pneumonia. Thirteen (10%) patients treated with Bu/Mel/T died secondary to infections. Five fatal infections were viral, four bacterial, two Pneumocystis carinii, one Mycobacterium avium and one fungal infection. Eight of 13 deaths from infections occurred in patients without prior dose-limiting radiation therapy.
Deaths from non-infectious etiology:
Hemorrhage was the cause of death in three patients with aggressive NHL conditioned with the TBI-based regimen. Overall TRM occurred in 36 (16%) patients receiving TBI/CY/E and in 27 (21%) patients after Bu/Mel/T therapy (16% vs 21% P = 0.8). Fourteen (20%) of 71 patients without dose-limiting radiation therapy and 13 (22%) of 59 patients who had dose-limiting radiation therapy died from transplant complications. No statistically significant differences were observed in TRM rates between TBI/CY/E and Bu/Mel/T, irrespective of the disease status before transplantation and the history of prior radiation therapy ( Table 2) .
The TRM for patients receiving TBI (n = 140) and Bu/Mel/T (n = 123) followed by PBSC infusion was 13% and 21%, respectively. Of 123 patients receiving Bu/Mel/T 66 (54%) had prior dose-limiting irradiation and the TRM was 20%. The TRM for patients in first remission (TBI, n = 9; Bu/Mel/T, n = 7) or first partial remission (TBI, n = 34; Bu/Mel/T, n = 18) was 14% for TBI/CY/E and 28% for Bu/Mel/T. Eight (32%) of 25 patients receiving Bu/Mel/T had prior dose-limiting radiation therapy and the TRM for this subset of patients was 37%.
HDC regimen TBI/CY/E:
The median follow-up was 5 years (range 1-9) after transplantation. Seventy-three (33%) patients remain in continued remission, 107 (48%) have relapsed, and 80 (36%) died from disease progression. One patient who was diagnosed with glioblastoma multiforme died at day 446. Myelodysplasia and acute myeloid leukemia (MDS/AML) were diagnosed 3.5 and 4 years after transplantation in two patients with indolent lymphoma. Two patients were lost to follow-up and died of unknown causes.
Bu/Mel/T: With a median follow-up of 3.5 years (range 1-6) since transplantation, 49 patients (38%) remain in continued remission, 51 (39%) have relapsed and 37 (28%) died from disease progression. Two patients died of unknown causes.
Influence of prior dose-limiting radiation therapy and status of disease
There were no statistically significant differences in outcomes and toxicities between patients without dose-limiting radiation therapy and those who had prior dose-limiting irradiation (Table 2) .
Histology
No significant differences in efficacy and toxicities were observed between TBI/CY/E and Bu/Mel/T therapy for patients with indolent or aggressive lymphoma (Table 3) . Table 3 Outcomes for patients with NHL according to histology TRM = transplant-related mortality; RRT = regimen-related toxicity.
Survival
The 5-year cumulative estimates of survival, EFS and relapse for TBI/CY/E were 44%, 32% and 49% and 42%, 34% and 42% for Bu/Mel/T (Figure 1 ). The 5-year probability of EFS for patients with less advanced disease or more advanced disease status before transplantation were: TBI/CY/E 36% and 29% ( Figure 2a) ; Bu/Mel/T: 45% and 27% (Figure 2b ). The probabilities of EFS at 5-years for patients without dose-limiting irradiation (n = 71) was 35% and 32% for those who had prior dose-limiting radiation (n = 59) after Bu/Mel/T therapy. The probabilities of EFS at 5 years for patients with indolent lymphoma were 37% following TBI/CY/E and 36% following Bu/Mel/T. The cumulative incidence of EFS at 5 years for patients with aggressive lymphoma who had less advanced disease and more advance disease were 46% and 20% for TBI/CY/E and 40% and 26% for Bu/Mel/T (P = 0.2).
Prognostic factors
Univariate and Cox regression analyses identified more advanced disease status as an adverse prognostic factor for outcome, irrespective of the HDC regimen received (less advanced disease vs more advanced disease: all patients: 39% vs 28% P = 0.04; relative risk (RR) 0.65, 95% confidence intervals (CI) 0.50 to 0.86 P = 0.005; TBI/CY/E patients 36% vs 29% P = 0.05; RR 0.70, 95% CI 0.50 to 0.97, P = 0.04; Bu/Mel/T patients = 45% vs 27% P = 0.03; RR 0.61, 95% CI 0.39 to 0.97, P = 0.03). Aggressive his- tology and more advanced disease status were associated with worse outcome for the entire group of patients and those treated with the TBI/CY/E regimen compared to those who had aggressive histology and less advanced disease status: all patients 28 vs 39% P = 0.002; RR 1.10, 95% CI 1.02 to 1.18, P = 0.0008; TBI/CY/E patients: 20 vs 46% P = 0.007; RR 1.10, 95% CI 1.00 to 1.20, P = 0.03). No significant differences in outcomes were observed between patients with aggressive NHL receiving Bu/Mel/T (less advanced disease 40% vs 26% P = 0.2). None of the variables examined were significant for TRM or RRT.
Discussion
In this report, 221 patients with NHL were treated with TBI/CY/E and 130 with Bu/Mel/T followed by ASCI. No significant differences in efficacy and toxicity between the two regimens were demonstrated. A previous, nonrandomized study from Stanford University with a median follow-up of 4.3 years, did not find differences in survival, TRM, and relapse between TBI/CY/E (n = 134) and CBV (n = 87) regimens. 12 The present study reaches conclusions similar to the Stanford University experience and other studies reported. [13] [14] [15] The Memorial Sloan Kettering Cancer Center (MSKCC) and Stanford University 5, 12 have evaluated a similar TBI/CY/E regimen in patients with NHL. The probabilities of EFS at 3 and 5 years reported were 57% and 50%, respectively. The present study reports an inferior EFS at 5 years of 32%, but the difference in outcomes might be explained by the patient population evaluated. The MSKCC and Stanford University series included more patients who had sensitive disease: 35 (80%) of 44 patients and 125 (90%) of 134 patients, respectively, while in the FHCRC study, sensitive patients accounted for only 42% of the entire group. On the other hand, the 3-5 year EFS achieved with chemotherapy-only regimens for the treatment of patients with lymphoma have ranged between 46% and 35%. [9] [10] [11] [12] Although patients in our study had less favorable characteristics, the outcome of patients treated with highdose Bu/Mel/T regimen at the FHCRC is comparable to both the TBI-based and chemotherapy-only regimens reported in other trials. We did have somewhat more toxicity than would be expected from other regimens in the early phases of the trial. Since this has decreased in the last 3 years, we attribute this to a 'learning curve' regarding the management of patients on a new regimen. Furthermore, the outcomes of the patients who had dose-limiting radiation therapy are similar to those patients without prior dose-limiting radiation therapy. Although longer follow-up is required, the outcomes of patients who received Bu/Mel/T suggest a potential benefit for those with a history of prior dose-limiting radiation therapy.
Morbidity and toxicity secondary to HDC regimens have been reduced, but remain major problems. The MSKCC study 4 reported a TRM rate of 34% which was attributed to the higher TBI dose and the history of radiation therapy to sites of disease prior to transplantation. Stanford University, possibly due to patient selection, had reported reduced TRM and RRT rates of 9% and 7%, respectively. 5, 12 In our study, although the rate of RRT was similar to Stanford, the TRM rate was higher. Infectious deaths contributed with 7%. Since 12 of 15 infection-related deaths after TBI/CY/E therapy occurred within the first 3-4 years after introducing this regimen and later declined, this probably reflects improvements in supportive care, especially the introduction of PBSC over BM. TRM between 5% and 15% have been reported for drug-only regimens such as BEAC, 9,10 BEAM 11 and CBV. 12 IPS, VOD, and cardiac toxicity have been described as causes of death, and less than 10% have been associated with an infectious cause. The TRM and RRT of the Bu/Mel/T regimen although higher than those previously reported for other chemotherapy-only regimens could be explained by the characteristics of the population treated. Prior studies have reported a high morbidity and toxicity in those patients who had prior dose-limiting radiation therapy and more advanced disease. 30 In our series, 59 (45%) patients had dose-limiting radiation and received Bu/Mel/T regimen. Forty-one (69%) of these patients had more advanced disease and there were more patients greater than 60 years of age. Although the TRM and RRT rates were 29% and 19%, respectively, the outcome of this subgroup of patients was comparable to the entire group. Because the efficacy of Bu/Mel/T is similar to other drug-only regimens, studies are in progress to diminish the morbidity and mortality secondary to this regimen.
Since mucositis is a major toxicity of this regimen, we are evaluating the potential efficacy of keratinocyte growth factor in this setting.
Chemosensitive disease before transplantation has been identified as the most important prognostic factor predictive of favorable outcome after HDC/ASCI therapy. 2, 11, 12, 15 In our series, patients in first or second remission, patients in first sensitive relapse were defined as having less advanced disease status. In this study, as reported previously, 2, 11, 12, 15 this subset of patients benefited from transplantation, irrespective of the HDC received. Aggressive histology also has been associated with adverse outcome after conventional chemotherapy. Overall, 54% of patients included in our series had aggressive histology. Although not statistically significant, they tended to have a lower probability of EFS at 5 years compared to patients with indolent lymphoma. Aggressive histology, however, was an adverse prognostic factor for outcome when analyzed in combination with the status of disease before transplantation. Thus, patients of the entire group with more advanced disease and aggressive histology had the worst outcomes.
The role of HDC/ASCI in the treatment of patients with indolent lymphomas is controversial, since these patients often continue to relapse years after transplant. 6, 7, [33] [34] [35] Although the outcomes of the current study compare well with those series with longer follow-up, 33, 34 the relatively few patients in first or second remission preclude drawing definite conclusions. To date, longer follow-up and further clinical trials are required to establish the role of HDC/ASCI in the treatment of patients with indolent lymphoma. HDC/ASCI remains the standard treatment for patients with aggressive lymphoma in first or subsequent chemotherapy-sensitive relapse and for those patients who fail induction chemotherapy. 2 Our results support these observations. More controversial is the use of HDC/ASCI in high-risk (IPI 3-4 score) aggressive NHL in first complete remission. An ongoing national trial (SWOG 9704) is evaluating early vs delayed HDC/ASCI in those subgroups. In summary, our study did not show differences in outcomes or toxicity between a TBI-based and non-TBIcontaining regimen. Efforts to improve upon both approaches are needed.
